The historical rank and industry rank for Caribou Biosciences's Net Margin % or its related term are showing as below:
CRBU'
s Net Margin % Range Over the Past 10 Years
Min: -1491.95 Med: -697.26 Max: -277.55
Current: -1189.14
CRBU's Net Margin % is ranked worse than 80.25% of 947
companies
in the Biotechnology industry
Industry Median: -89.33
vs CRBU: -1189.14
Caribou Biosciences (NAS:CRBU) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Caribou Biosciences Net Margin % Related Terms
Caribou Biosciences Net Margin % Historical Data
* Premium members only.
The historical data trend for Caribou Biosciences's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Caribou Biosciences's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Caribou Biosciences Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Caribou Biosciences's Net Margin % distribution charts can be found below:
* The bar in red indicates where Caribou Biosciences's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Caribou Biosciences (CRBU) has a Net Margin % of -1,046.52% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Caribou Biosciences and its competitors. According to the industry distribution chart, Caribou Biosciences ranks #760 out of 947 companies in the Biotechnology industry, placing it in the top 80.3%.
Is Caribou Biosciences' Net Margin % too high?
Caribou Biosciences' current Net Margin % is -1,046.52%. Based on the distribution chart, Caribou Biosciences ranks #760 out of 947 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Caribou Biosciences has a GF Score™ of 66/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Caribou Biosciences' Net Margin % compare to OBIO and VYGR?
According to the Biotechnology industry distribution chart, Caribou Biosciences ranks #760 out of 947 companies for Net Margin %. This places Caribou Biosciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Caribou Biosciences and its competitors. Caribou Biosciences's current Net Margin % is -1,046.52%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Caribou Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Caribou Biosciences (CRBU) is currently considered Fairly Valued. The stock's GF Value™ is $1.70, compared to a current price of $1.66 — trading 2.4% below its estimated fair value. The current Net Margin % is -1,046.52%. Caribou Biosciences' overall GF Score™ is 66/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Caribou Biosciences (CRBU), the current Net Margin % is -1,046.52% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Caribou Biosciences (CRBU) Overvalued in 2026?
Based on GuruFocus' analysis, Caribou Biosciences stock appears to be undervalued.
The current stock price of $1.66 is trading 2.4% below its estimated GF Value™ of $1.70.
GuruFocus considers Caribou Biosciences to be Fairly Valued.
Key valuation signals for CRBU:
Net Margin %: -1,046.52%
GF Value™: $1.70 vs. price of $1.66 (2.4% below fair value)
No single metric tells the full story. See the CRBU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.
66GF Score
Get the complete analysis for CRBU
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CRBU has been successfully added to your 
